PDCD1 and head and neck squamous cell carcinoma: The affirmative results from the CheckMate 141 and KEYNOTE-048 trials validated that the PD-1 inhibitors improve survival and response in HNSCC patients compared to the single agent or single agent with chemotherapy group [19,20].